pharmaceutical company

Eli Lilly and Company

Industry Health

A major shareholder-governed pharmaceutical company with important medicines, including insulin and metabolic drugs, but serious affordability and historical marketing-abuse concerns. Eli Lilly and Company remains weak because of documented human harm, person-dependent governance, and material opacity, even where the product or service has practical value.

Why this matters: Lilly is a key pharma calibration case because lifesaving products can coexist with pricing power and access harms.

Letter grade F Malignant Medium confidence (AI) Rubric gcd-rubric-v1 Last reviewed May 6, 2026

Final Score -5* F - Malignant

FMALIGNANT-5 pts

* Tentative scaffolding score. Not human-checked or final.

Base Material27

Bonus+0

Cap35Ownership <= 2 and Governance <= 2

After Cap27

Penalties-32

Private Government badge

Eli Lilly and Company receives the Private Government badge because it combines large-scale private rule-setting over customers, workers, users, members, or counterparties with OpenLobby-documented lobbying of about $1.6M on public policy issues.

Evidence: [9]

!Not Verified

Represent this organization?

Request verification to have the evidence record checked against primary materials and organization-supplied documents. Verification does not buy a higher score; scores change only when review finds factual errors, omissions, or miscalibration.

Request verification

Evaluation Overview

F - Malignant

The score turns mainly on Product Integrity, with the largest penalty coming from Human Harm.

Strengths

Product Integrity5/5
Labor Sovereignty4/7
Loss-Bearing Fidelity4/7

Penalties

Human Harm-12
Policy Capture-6
Animal Testing-6
Reversibility-5

Evidence state

ConfidenceMedium confidence (AI)
ThoroughnessPartial (AI)
Linked claims9
Direct axis claims8
Coverage8/15

Scoring Axes

Axis	Score	Why this score
Ownership ? Control rights: shareholder-dominated at 0, worker cooperative control at 10.	1 / 10	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That keeps Eli Lilly and Company low on Ownership: decisive control remains with shareholders, private owners, executives, or state insiders rather than affected people. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 12 scored entries below, 65 tied, 149 above on Ownership. Uncertainty Priority page: add more axis-specific research over time to make the comparative placement harder to dispute. Linked evidence Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1]
Governance ? Binding decision authority: centralized control at 0, democratic stakeholder control at 10.	2 / 10	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That keeps Eli Lilly and Company low on Governance: ordinary users, workers, customers, or affected communities cannot change the rules that govern them. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 71 scored entries below, 22 tied, 133 above on Governance. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Extraction ? Surplus allocation, wage share, CEO pay ratio, margins, and structured extraction judgment.	3 / 10	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That keeps Eli Lilly and Company low on Extraction: the business model makes extraction from workers, users, suppliers, customers, or the public central rather than incidental. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 39 scored entries below, 22 tied, 165 above on Extraction. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Labor Sovereignty ? Worker power: coercive conditions at 0, co-determination or ownership at 7. Employee dissatisfaction matters only when source-backed evidence shows concrete limits on worker agency, such as coercive scheduling, retaliation, wage theft, harassment, unsafe conditions, suppression of worker voice, or extreme turnover.	4 / 7	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That places Eli Lilly and Company in the middle of Labor Sovereignty: workers or participants have some protection or agency, but not enough binding power to control the relationship. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 112 scored entries below, 39 tied, 75 above on Labor Sovereignty. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Solidarity with the Unemployed ? Treatment of exits and nonworkers, including severance, redeployment, and non-competes.	3 / 7	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That places Eli Lilly and Company in the middle of Solidarity with the Unemployed: some access, severance, retraining, openness, or mutual-aid value is present, but it is not central or durable. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 81 scored entries below, 45 tied, 100 above on Solidarity with the Unemployed. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Loss-Bearing Fidelity ? Willingness to absorb costs to preserve values, workers, users, and public obligations.	4 / 7	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That places Eli Lilly and Company in the middle of Loss-Bearing Fidelity: there is some willingness to preserve obligations, but the record still leaves meaningful risk-shifting concerns. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 88 scored entries below, 30 tied, 108 above on Loss-Bearing Fidelity. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Market Conduct ? Pricing fairness, switching costs, lock-in, and rent extraction.	2 / 5	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That places Eli Lilly and Company in the middle of Market Conduct: the product has real value but still uses meaningful lock-in, gatekeeping, market power, or dependency. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 31 scored entries below, 22 tied, 173 above on Market Conduct. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Product Integrity ? Preservation of quality rather than degradation for monetization.	5 / 5	Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. That places Eli Lilly and Company high on Product Integrity: the core offering is genuinely useful and comparatively less dependent on traps, degradation, or harmful dependencies. A still-higher or maximum value requires stronger proof that this structure is durable, broad, and not merely discretionary. Calibration notes Comparative anchor: Column-spectrum position: 134 scored entries below, 92 tied, 0 above on Product Integrity. Uncertainty Priority page: add more axis-specific research over time to make the comparative placement harder to dispute. Linked evidence Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]
Scale Integrity ? Whether growth improves or degrades fairness and accountability.	3 / 5	Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. That places Eli Lilly and Company in the middle of Scale Integrity: scale brings useful reach but also weakens accountability, transparency, or local constraint. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 50 scored entries below, 58 tied, 118 above on Scale Integrity. Linked evidence context Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company. [1] context Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used. [2]

Penalties

Penalty	Applied	Why this penalty
Reversibility ? Applied when positive conduct depends on current living leaders, founders, family owners, or other person-contingent governance rather than durable structure. Range: -5 to 0.	-5	Eli Lilly positive conduct depends on corporate leadership, patent strategy, pricing policy, regulation, and investor governance rather than structurally democratic patient, worker, or public control. Eli Lilly positive conduct depends on corporate leadership, patent strategy, pricing policy, regulation, and investor governance rather than structurally democratic patient, worker, or public control. That warrants a severe Reversibility penalty because favorable conduct depends on current people or discretionary leadership rather than locked stakeholder structure. The value is near the floor because the conduct appears central, large-scale, repeated, or institutionally powerful rather than incidental. Calibration notes Comparative anchor: Column-spectrum position: 0 scored entries below, 95 tied, 131 above on Reversibility. Linked evidence Eli Lilly positive conduct depends on corporate leadership, patent strategy, pricing policy, regulation, and investor governance rather than structurally democratic patient, worker, or public control. [3]
Human Harm ? Severity, scale, culpability, vulnerable targets, willful reoffense, reputation laundering, pattern escalation, and time decay. Range: -20 to 0.	-12	Eli Lilly insulin pricing controversy and the DOJ Zyprexa settlement describes conduct considered under Human Harm access and marketing-abuse risk. Eli Lilly insulin pricing controversy and the DOJ Zyprexa settlement describes conduct considered under Human Harm access and marketing-abuse risk. That warrants a substantial Human Harm penalty because ordinary operation, documented misconduct, or institutional power creates serious injury, deprivation, abuse, or foreseeable human damage. The value is substantial but not at the floor because the linked record shows serious conduct without the strongest aggravating factors on this axis. Calibration notes Comparative anchor: Column-spectrum position: 20 scored entries below, 3 tied, 203 above on Human Harm. Linked evidence Eli Lilly insulin pricing controversy and the DOJ Zyprexa settlement describes conduct considered under Human Harm access and marketing-abuse risk. [4]
Policy Capture ? Private-interest attempts to bend law, regulation, subsidies, taxes, enforcement, trade, labor, safety, competition, environmental, healthcare, housing, surveillance, civil-liberties, or consumer policy against workers, customers, citizens, affected communities, or ecological life. Public-interest advocacy is not penalized merely because it is lobbying. Range: -15 to 0.	-6	OpenLobby records ELI LILLY & COMPANY lobbying on Medicare / Medicaid, healthcare, budget, tax, defense, trade, and other issues with about $1.6M in spending across 32 filings; the reviewed… OpenLobby records ELI LILLY & COMPANY lobbying on Medicare / Medicaid, healthcare, budget, tax, defense, trade, and other issues with about $1.6M in spending across 32 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role. That warrants a substantial Policy Capture penalty because private institutional pressure is being applied to public rules while affected people cannot democratically govern that agenda. The value is substantial but not at the floor because the linked record shows serious conduct without the strongest aggravating factors on this axis. Linked evidence OpenLobby records ELI LILLY & COMPANY lobbying on Medicare / Medicaid, healthcare, budget, tax, defense, trade, and other issues with about $1.6M in spending across 32 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role. [7]
Animal Testing ? Direct animal testing, contract animal testing, animal-testing-dependent product development, or business lines where current safety/regulatory approval normally relies on animal experiments. Stronger penalties apply where animal testing is core, repeated, non-optional, or avoidable; documented cruelty-free or non-animal methods reduce or eliminate the penalty. Range: -8 to 0.	-6	Pharmaceutical, medical-product, or drug-development business models remain structurally tied to animal-testing systems in current regulated product development. Linked evidence Eli Lilly and Company has drug/medical product development animal-testing exposure based on its listed business model and current profile description: A major shareholder-governed pharmaceutical company with important medicines, including insulin and metabolic drugs, but serious affordability and historical marketing-abuse concerns. Eli Lilly and Company remains weak… [8]
Accountability Opacity ? Material opacity, reputation laundering, or hidden accountability structures that prevent public accountability. Range: -2 to 0.	-2	Eli Lilly pricing and marketing controversies is relevant to the accountability-opacity penalty because public accountability depends on regulatory, litigation, and pricing-system scrutiny. Eli Lilly pricing and marketing controversies is relevant to the accountability-opacity penalty because public accountability depends on regulatory, litigation, and pricing-system scrutiny. That warrants a severe Accountability Opacity penalty because material facts, risks, conflicts, ownership, or accountability information are obscured from the public. The value is near the floor because the conduct appears central, large-scale, repeated, or institutionally powerful rather than incidental. Calibration notes Comparative anchor: Column-spectrum position: 0 scored entries below, 52 tied, 174 above on Accountability Opacity. Linked evidence Eli Lilly pricing and marketing controversies is relevant to the accountability-opacity penalty because public accountability depends on regulatory, litigation, and pricing-system scrutiny. [5]
Ideological Disavowal ? Concealed ideology presented as neutrality, expertise, professional necessity, public-service administration, market inevitability, or non-ideological common sense while exercising power. Range: -3 to 0.	-1	Eli Lilly and Company's public framing is assessed as ideological-disavowal evidence because Eli Lilly and Company shows bounded neutrality theater: some contested choices are softened… Eli Lilly and Company's public framing is assessed as ideological-disavowal evidence because Eli Lilly and Company shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment. That warrants a limited Ideological Disavowal penalty because the institution presents situated, contested choices as neutrality, expertise, inevitability, safety, or common sense. The value is limited because the linked record shows a real problem but not one that dominates the profile on this axis. Calibration notes Comparative anchor: Ideological Disavowal 0 to -3 recalibration: 0 for explicit standpoint or no penalty-level neutrality theater; -1 for bounded softening of contested choices; -2 for strong neutrality theater by a powerful institution; -3 for major gatekeeping or coercive power presented as neutral, necessary, objective, or non-ideological. Uncertainty This recalibration uses public self-presentation and profile evidence; later review should add direct language-analysis evidence for high-impact institutions. Linked evidence Eli Lilly and Company's public framing is assessed as ideological-disavowal evidence because Eli Lilly and Company shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment of standpoint. [6]

Bonus Credits

No bonus credits applied in this version.

Confidence Basis

Confidence is computed from the evidence trail and review state, not typed into the profile by hand.

Medium 74/100

8 verified linked claims 8 direct axis claims 0 disputed claims 8/15 components covered

This confidence label measures the source-backed evidence trail. AI-scaffolded scores remain tentative until human review.

Claim confidence 17/20

8 verified linked claims

Source quality 14/18

Best source per verified claim, weighted by institutional reliability

Direct axis-specific claims 9/18

8 direct claims across 15 active components

Dispute load 12/12

0 disputed claims on this entity

Recency 10/10

Newest accepted timestamp: May 13, 2026

Reviewer status 7/12

Human-reviewed components score higher than AI scaffolding

Component coverage 5/10

8/15 evidence-bearing components have direct support

Evidence State

Profile stateAI draft / human-pending

VerificationUnverified

ConfidenceMedium confidence (AI)

ThoroughnessPartial (AI)

Correction routeUse “Challenge this rating” for factual errors, missing counterevidence, source problems, or calculation mistakes.

Company responseCompany representatives can submit source-backed corrections; payment never changes scores or reviewer authority.

Claims and Sources

Claims are the evidence record. Each claim needs a source link, axis category, status, confidence level, and timestamp before it can support a score.

* Tentative scaffolding score. Not human-checked or final.

1Eli Lilly publishes investor-relations and annual-report materials for a shareholder-governed public pharmaceutical company.

Ownership Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

Eli Lilly investor relationsOfficial self-description · 68%

2Eli Lilly develops and sells medicines including insulin and other treatments that can provide high direct health value when accessible and appropriately used.

Product Integrity Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

Lilly medicinesGeneral web source · 58%

3Eli Lilly positive conduct depends on corporate leadership, patent strategy, pricing policy, regulation, and investor governance rather than structurally democratic patient, worker, or public control.

Reversibility Verified Medium confidence AI-generated / human-pending May 6, 2026

AI scaffold

Eli Lilly investor relationsOfficial self-description · 68%

4Eli Lilly insulin pricing controversy and the DOJ Zyprexa settlement describes conduct considered under Human Harm access and marketing-abuse risk.

Human Harm Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

FTC insulin intermediary and manufacturer scrutinyPrimary public record · 100%
DOJ Eli Lilly Zyprexa settlementPrimary public record · 100%

5Eli Lilly pricing and marketing controversies is relevant to the accountability-opacity penalty because public accountability depends on regulatory, litigation, and pricing-system scrutiny.

Accountability Opacity Verified Medium confidence AI-generated / human-pending May 6, 2026

AI scaffold

FTC prescription drug middlemen reportPrimary public record · 100%
DOJ Eli Lilly Zyprexa settlementPrimary public record · 100%

6Eli Lilly and Company's public framing is assessed as ideological-disavowal evidence because Eli Lilly and Company shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment of standpoint.

Ideological Disavowal Verified Medium confidence AI-generated / human-pending May 9, 2026

AI scaffold

Eli Lilly and Company official siteGeneral web source · 58%
Eli Lilly investor relationsOfficial self-description · 68%
Lilly medicinesGeneral web source · 58%

7OpenLobby records ELI LILLY & COMPANY lobbying on Medicare / Medicaid, healthcare, budget, tax, defense, trade, and other issues with about $1.6M in spending across 32 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role.

Policy Capture Verified Medium confidence AI-generated / human-pending May 11, 2026

AI scaffold

OpenLobby — ELI LILLY & COMPANY lobbying profileGeneral web source · 58%

8Eli Lilly and Company has drug/medical product development animal-testing exposure based on its listed business model and current profile description: A major shareholder-governed pharmaceutical company with important medicines, including insulin and metabolic drugs, but serious affordability and historical marketing-abuse concerns. Eli Lilly and Company remains weak…

Animal Testing Verified High confidence Human-reviewed May 11, 2026

Eli Lilly and Company public siteGeneral web source · 58%
FDA: Animal Welfare, Testing and Research of FDA-Regulated ProductsPrimary public record · 100%

9Eli Lilly and Company receives the Private Government badge because it combines large-scale private rule-setting over customers, workers, users, members, or counterparties with OpenLobby-documented lobbying of about $1.6M on public policy issues.

Private Government Verified Medium confidence AI-generated / human-pending May 11, 2026

AI scaffold

OpenLobby — ELI LILLY & COMPANY lobbying profileGeneral web source · 58%

Alternatives

Competitors

AGOOD66 Patient Advocate Foundation nonprofit patient case-management and financial-aid resource · same market AGOOD54 Federally Qualified Health Centers publicly supported community health-center system · same market AGOOD53 OpenNotes academic healthcare-transparency initiative · same market AGOOD50 CPESN USA network of independent community pharmacies · same market BQUALIFIED49 Civica Rx nonprofit generic medicine company · same market BQUALIFIED43 Planned Parenthood nonprofit reproductive and sexual healthcare federation · same market CPERFORMATIVE41 En-Vision America / ScriptAbility accessible prescription-labeling company · same market CPERFORMATIVE41 Mark Cuban Cost Plus Drug Company public-benefit online pharmacy · same market

Help Improve This Profile

Submit source-backed evidence or challenge a specific claim, source, axis value, or calculation below.

How This Page Is Maintained

Evidence comes in through contributors, is checked by verifiers, and is synthesized by reviewers. Founder authority remains narrow and visible; scores recalculate when verified claims or the rubric change.

Civic Note

Incorporation, limited liability, market access, and other institutional privileges are public grants. Good Companies Directory treats those privileges as conditional on accountability to workers, users, communities, and the public.

Submit evidence for Eli Lilly and Company Add one source-backed fact for review.

Challenge this rating Point to a specific score, claim, source, or calculation problem.

Audit Log

Recent public changes for this company or group. The full audit log is part of the Transparency record.

May 6, 2026 at 12:00 AM UTC ai-scaffolding

View Full Audit Log